Search International and National Patent Collections
Some content of this application is unavailable at the moment.
If this situation persists, please contact us atFeedback&Contact
1. (WO2017098733) INDOLE ACETIC ACID DERIVATIVE
Latest bibliographic data on file with the International Bureau

Pub. No.: WO/2017/098733 International Application No.: PCT/JP2016/005100
Publication Date: 15.06.2017 International Filing Date: 09.12.2016
IPC:
C07D 209/18 (2006.01) ,A61K 31/405 (2006.01) ,A61K 31/407 (2006.01) ,A61K 31/444 (2006.01) ,A61P 3/00 (2006.01) ,A61P 9/00 (2006.01) ,A61P 9/04 (2006.01) ,A61P 9/10 (2006.01) ,A61P 13/12 (2006.01) ,A61P 21/00 (2006.01) ,A61P 21/04 (2006.01) ,A61P 25/00 (2006.01) ,A61P 25/08 (2006.01) ,A61P 25/16 (2006.01) ,A61P 25/28 (2006.01) ,A61P 27/02 (2006.01) ,A61P 43/00 (2006.01) ,C07D 401/04 (2006.01) ,C07D 409/06 (2006.01) ,C07D 491/056 (2006.01)
C CHEMISTRY; METALLURGY
07
ORGANIC CHEMISTRY
D
HETEROCYCLIC COMPOUNDS
209
Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
02
condensed with one carbocyclic ring
04
Indoles; Hydrogenated indoles
10
with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
18
Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
K
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31
Medicinal preparations containing organic active ingredients
33
Heterocyclic compounds
395
having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
40
having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
403
condensed with carbocyclic rings, e.g. carbazole
404
Indoles, e.g. pindolol
405
Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
K
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31
Medicinal preparations containing organic active ingredients
33
Heterocyclic compounds
395
having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
40
having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
407
condensed with heterocyclic ring systems, e.g. ketorolac, physostigmine
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
K
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31
Medicinal preparations containing organic active ingredients
33
Heterocyclic compounds
395
having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
435
having six-membered rings with one nitrogen as the only ring hetero atom
44
Non-condensed pyridines; Hydrogenated derivatives thereof
4427
containing further heterocyclic ring systems
444
containing a six-membered ring with nitrogen as a ring hetero atom, e.g. amrinone
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
P
SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
3
Drugs for disorders of the metabolism
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
P
SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
9
Drugs for disorders of the cardiovascular system
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
P
SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
9
Drugs for disorders of the cardiovascular system
04
Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
P
SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
9
Drugs for disorders of the cardiovascular system
10
for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
P
SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
13
Drugs for disorders of the urinary system
12
of the kidneys
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
P
SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
21
Drugs for disorders of the muscular or neuromuscular system
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
P
SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
21
Drugs for disorders of the muscular or neuromuscular system
04
for myasthenia gravis
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
P
SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
25
Drugs for disorders of the nervous system
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
P
SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
25
Drugs for disorders of the nervous system
08
Antiepileptics; Anticonvulsants
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
P
SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
25
Drugs for disorders of the nervous system
14
for treating abnormal movements, e.g. chorea, dyskinesia
16
Anti-Parkinson drugs
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
P
SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
25
Drugs for disorders of the nervous system
28
for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
P
SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
27
Drugs for disorders of the senses
02
Ophthalmic agents
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
P
SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
43
Drugs for specific purposes, not provided for in groups A61P1/-A61P41/108
C CHEMISTRY; METALLURGY
07
ORGANIC CHEMISTRY
D
HETEROCYCLIC COMPOUNDS
401
Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
02
containing two hetero rings
04
directly linked by a ring-member-to-ring- member bond
C CHEMISTRY; METALLURGY
07
ORGANIC CHEMISTRY
D
HETEROCYCLIC COMPOUNDS
409
Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
02
containing two hetero rings
06
linked by a carbon chain containing only aliphatic carbon atoms
C CHEMISTRY; METALLURGY
07
ORGANIC CHEMISTRY
D
HETEROCYCLIC COMPOUNDS
491
Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/-C07D459/290
02
in which the condensed system contains two hetero rings
04
Ortho-condensed systems
056
with two or more oxygen atoms as ring hetero atoms in the oxygen-containing ring
Applicants:
株式会社 東北テクノアーチ TOHOKU TECHNO ARCH CO., LTD. [JP/JP]; 宮城県仙台市青葉区荒巻字青葉468番地 468, Aza Aoba, Aramaki, Aoba-ku, Sendai-shi, Miyagi 9800845, JP
大日本住友製薬株式会社 SUMITOMO DAINIPPON PHARMA CO., LTD. [JP/JP]; 大阪府大阪市中央区道修町2丁目6番8号 6-8, Dosho-machi 2-chome, Chuo-ku, Osaka-shi, Osaka 5418524, JP
Inventors:
阿部 高明 ABE, Takaaki; JP
深谷 孝幸 FUKAYA, Takayuki; JP
片岡 真由美 KATAOKA, Mayumi; JP
北原 克志 KITAHARA, Katsushi; JP
石田 恭次 ISHIDA, Kyoji; JP
Agent:
廣田 雅紀 HIROTA, Masanori; JP
Priority Data:
2015-24101910.12.2015JP
Title (EN) INDOLE ACETIC ACID DERIVATIVE
(FR) DÉRIVÉ DE L'ACIDE INDOLE ACÉTIQUE
(JA) インドール酢酸誘導体
Abstract:
(EN) Provided is a compound represented by formula (I) or a pharmaceutically acceptable salt thereof, which exhibits an effect of significant inhibition on cell death induced in cells of patients with diseases associated with abnormalities in mitochondrial function. Therefore, the compound or a pharmaceutically acceptable salt thereof is useful as a therapeutic agent and/or prophylactic agent for diseases associated with abnormalities in mitochondrial function, such as mitochondrial diseases, neurodegenerative diseases, immune neurological diseases, cerebral ischemic diseases, renal diseases, muscular diseases, and cardiac diseases. [In formula (I), Xa, Xb, Xc, and Xd each independently represent, for example, a hydrogen atom, a halogen atom, a trifluoromethyl group, a phenyl group, or a cyclohexyl group; and A is, for example, a group represented by formula (II) (in the formula, Ya, Yb, Yc, Yd, and Ye each independently represent, for example, a hydrogen atom, a halogen atom, a t-butyl group, or a trifluoromethyl group).]
(FR) L'invention concerne un composé représenté par la formule (I) ou son sel de qualité pharmaceutique, présentant un effet d'inhibition important sur la mort cellulaire induite dans des cellules de patients souffrant de maladies associées à des anomalies de la fonction mitochondriale. Par conséquent, le composé ou son sel de qualité pharmaceutique est utile en tant qu'agent thérapeutique et/ou agent prophylactique pour des maladies associées à des anomalies de la fonction mitochondriale, telles que des maladies mitochondriales, des maladies neurodégénératives, des maladies neurologiques d’origine immunitaire, des maladies ischémiques cérébrales, des maladies rénales, des maladies musculaires, et des maladies cardiaques. [Dans la formule (I), Xa, Xb, Xc, et Xd représentent chacun indépendamment, par exemple, un atome d'hydrogène, un atome d'halogène, un groupe trifluorométhyle, un groupe phényle, ou un groupe cyclohexyle ; et A désigne, par exemple, un groupe représenté par la formule (II) (dans la formule, Ya, Yb, Yc, Yd, et Ye représentent indépendamment, par exemple, un atome d'hydrogène, un atome d'halogène, un groupe t-butyle, ou un groupe trifluorométhyle).]
(JA) 下記式(I)で表される化合物またはその製薬学的に許容される塩は、ミトコンドリア機能の異常が関わる疾患の患者の細胞で誘発される細胞死に対して顕著な細胞死抑制作用を示す。したがって、当該化合物またはその製薬学的に許容される塩は、ミトコンドリア機能の異常が関わる疾患、例えば、ミトコンドリア病、神経変性疾患、免疫性神経疾患、脳虚血性疾患、腎疾患、筋疾患、心疾患に対する治療剤及び/又は予防剤として有用である。 [式(I)中、X、X、XおよびXは、それぞれ独立して、例えば、水素原子、ハロゲン原子、トリフルオロメチル基、フェニル基、またはシクロヘキシル基を表し;Aは、例えば、下記式(II): (式中、Y、Y、Y、YおよびYは、それぞれ独立して、例えば、水素原子、ハロゲン原子、t-ブチル基、またはトリフルオロメチル基を表す)で表される基である。]
front page image
Designated States: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW
African Regional Intellectual Property Organization (ARIPO) (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW)
Eurasian Patent Organization (AM, AZ, BY, KG, KZ, RU, TJ, TM)
European Patent Office (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR)
African Intellectual Property Organization (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG)
Publication Language: Japanese (JA)
Filing Language: Japanese (JA)